Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer

• Published in: Biology direct 2024-08, Vol.19 (1), p.65-15
• Main Authors: Liu, Zitao, Sun, Liang, Zhu, Wenjie, Zhu, Jinfeng, Wu, Changlei, Peng, Xingyu, Tian, Huakai, Huang, Chao, Zhu, Zhengming
• Format: Article
• Language: English
• Subjects: Algorithms; Antibodies; Apoptosis; Cancer; Cancer therapies; Cell death; Cell Line, Tumor; Cell migration; Cell proliferation; Clustering; Collagen (type X); Customization; Disulfidptosis; Ferroptosis; Gastric cancer; Genes; Health aspects; Humans; Immune response; Immune system; Immunohistochemistry; Immunology; Immunotherapy; Medical prognosis; Metastases; Oncology, Experimental; Physiological aspects; Prognosis; Proteins; Stomach cancer; Stomach Neoplasms - genetics; Stomach Neoplasms - immunology; Survival analysis; Tumor microenvironment; Tumor Microenvironment - immunology; Tumors; Wound healing
• ISSN: 1745-6150; 1745-6150
• DOI: 10.1186/s13062-024-00518-6

Disulfidptosis is a newly identified mechanism of cell death triggered by disulfide stress. Thus, gaining a comprehensive understanding of the disulfidptosis signature present in gastric cancer (GC) could greatly enhance the development of personalized treatment strategies for this disease. We employed consensus clustering to identify various subtypes of disulfidptosis and examined the distinct tumor microenvironment (TME) associated with each subtype. The Disulfidptosis (Dis) score was used to quantify the subtype of disulfidptosis in each patient. Subsequently, we assessed the predictive value of Dis score in terms of GC prognosis and immune efficacy. Finally, we conducted in vitro experiments to explore the impact of Collagen X (COL10A1) on the progression of GC. Two disulfidptosis-associated molecular subtypes (Discluster A and B) were identified, each with distinct prognosis, tumor microenvironment (TME), immune cell infiltration, and biological pathways. Discluster A, characterized by high expression of disulfidptosis genes, exhibited a high immune score but poor prognosis. Furthermore, the Dis score proved useful in predicting the prognosis and immune response in GC patients. Those in the low Dis score group showed better prognosis and increased sensitivity to immunotherapy. Finally, our experimental findings validated that downregulation of COL10A1 expression attenuates the proliferation and migration capabilities of GC cells while promoting apoptosis. This study demonstrates that the disulfidptosis signature can assist in risk stratification and personalized treatment for patients with GC. The results offer valuable theoretical support for anti-tumor strategies.